Humira Biosimilar Market Is Estimated To Witness High Growth Owing To Increasing Demand for Cost-effective and Safe Treatment Options

Humira Biosimilar Market
Humira Biosimilar Market


The global Humira Biosimilar Market is estimated to be valued at US$ 772.1 million in 2023 and is expected to exhibit a CAGR of 25.9% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.


Market Overview:
Humira biosimilars are biologic drugs that are highly similar to the reference product Humira, which is used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn's disease. These biosimilars offer similar efficacy and safety profiles as the reference product but at a lower cost, making them an attractive treatment option for patients and healthcare providers alike. The increasing prevalence of autoimmune diseases, coupled with the need for cost-effective alternative treatments, is driving the demand for Humira biosimilars.

Market Key Trends:
One key trend in the Humira biosimilar market is the introduction of new biosimilars by major players. Companies such as Amgen Inc., Samsung Bioepis Co., Ltd., and Sandoz International GmbH (Novartis AG) are actively developing and launching biosimilar versions of Humira. This is expected to increase competition in the market, leading to lower prices and greater accessibility for patients.

Furthermore, the expiration of Humira's patent in various regions is opening up opportunities for new entrants in the market. This is expected to further drive the growth of the Humira biosimilar market. Additionally, increasing investments in research and development activities aimed at developing more advanced biosimilars with enhanced therapeutic efficacy and improved patient outcomes are anticipated to contribute to market growth.

Overall, the Humira biosimilar market is poised for high growth, driven by the increasing demand for cost-effective and safe treatment options for autoimmune diseases. The introduction of new biosimilars and the expiration of patents are

PEST Analysis:

Political: The political environment plays a crucial role in the humira biosimilar market. Government regulations and policies regarding the approval and pricing of biosimilars impact the market dynamics. For example, favorable regulations and initiatives promoting the use of biosimilars can boost market growth.

Economic: The economic factors influencing the humira biosimilar market include healthcare expenditure, affordability of biosimilars, and reimbursement policies. Economic growth in emerging markets and cost-effectiveness of biosimilars compared to the reference product can drive market growth.

Social: Changing healthcare trends and increasing awareness about biosimilars among healthcare professionals and patients are social factors impacting the market. The growing preference for cost-effective treatment options and the need for increased access to biologics drive the adoption of biosimilars.

Technological: Technological advancements in biotechnology, manufacturing processes, and storage technologies influence the humira biosimilar market. Developments in analytics and quality control techniques enhance the manufacturing and safety standards of biosimilars, contributing to market growth.

Key Takeaways:

The global humira biosimilar market is expected to witness high growth, exhibiting a CAGR of 25.9% over the forecast period (2023-2030). The market's growth can be attributed to increasing demand for cost-effective treatment options and the patent expiry of the reference biologic. The rising prevalence of autoimmune diseases also drives the adoption of biosimilars.

In terms of regional analysis, North America is expected to be the fastest-growing and dominating region in the humira biosimilar market. Factors such as favorable government regulations, extensive R&D activities, and a robust healthcare infrastructure contribute to market growth in this region.

Key players operating in the humira biosimilar market include Amgen Inc., Samsung Bioepis Co., Ltd., Sandoz International GmbH (Novartis AG), Mylan N.V., Boehringer Ingelheim International GmbH, Pfizer Inc., Fresenius Kabi AG, Coherus BioSciences, Inc., Biogen Inc., AbbVie Inc., Celltrion Inc., Amneal Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., Merck & Co., Inc., and Viatris Inc. These companies are focused on strategic collaborations, mergers and acquisitions, and product launches to strengthen their market position and expand their product portfolio.
Read More:
https://www.newsstatix.com/the-promising-future-of-the-humira-biosimilar-market-market-overview/
 

Comments

Post a Comment

Popular posts from this blog

Integration of Internet of Things (IoT) in the Drug Device Combination Product Market Industry

Image
Drug Device Combination Product Market The integration of the Internet of Things (IoT) in the Drug Device Combination Product Market Industry has the potential to revolutionize patient care, enhance treatment outcomes, and transform healthcare delivery. IoT refers to the network of interconnected devices that collect and exchange data through the internet. When applied to drug device combination products, IoT enables real-time monitoring, remote patient management, and data-driven insights that can greatly improve the effectiveness and efficiency of healthcare. One of the key benefits of IoT integration in the industry is remote patient monitoring. Connected drug device combination products equipped with sensors and connectivity capabilities can collect patient data, such as vital signs, medication adherence, and symptom tracking. This data is transmitted in real-time to healthcare providers, enabling them to monitor patients remotely and make timely interventions. Remote monitoring
Read more

Global Optical Transceiver Market Is Estimated To Witness High Growth Owing To Rising Demand for High-Speed Data Transfer

Image
Optical Transceiver Market  The global optical transceiver market is estimated to be valued at US$ 10.05 billion in 2022 and is expected to exhibit a CAGR of 12.2% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Optical transceivers are devices used in fiber optic communication networks to transmit and receive data. They convert electrical signals into optical signals for transmission over optical fibers. These transceivers offer several advantages, including high data transfer rates, long-range transmission capabilities, and immunity to electromagnetic interference. The need for high-speed data transfer and the growing demand for bandwidth-intensive applications are driving the adoption of optical transceivers in various industries. Market Key Trends: One key trend observed in the optical transceiver market is the increasing demand for higher data transfer speeds. With the proliferation of cloud computing, st
Read more

Positron Emission Tomography (PET) Scanners Market: Emerging Applications in Drug Development and Clinical Trials

Image
Positron Emission Tomography (PET) Scanners Market Positron Emission Tomography (PET) scanners have emerged as powerful tools with diverse applications in the field of medical imaging. Beyond their well-established role in clinical diagnostics, PET scanners are increasingly being utilized in drug development and clinical trials. The unique capabilities of PET imaging enable researchers and pharmaceutical companies to gain valuable insights into drug behavior, target engagement, and treatment efficacy, thereby revolutionizing the drug development process. One of the primary applications of PET scanners in drug development is the assessment of drug pharmacokinetics. PET imaging allows researchers to track the distribution, metabolism, and elimination of radiolabeled drugs in real-time. By monitoring the drug's journey in the body, researchers can identify potential drug-drug interactions, evaluate the drug's bioavailability, and optimize dosing regimens. Additionally, PET sca
Read more